

Transparency notification Wellington Management Group LLP

Brussels (Belgium), 31 August 2026 – 20:00 (CEST) – Regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from Wellington Management Group LLP. (having its registered office at 280 Congress Street, Boston, MA 02210, USA.) on 26 August 2026.

Wellington Management Group LLP, notified that, following an acquisition of UCB shares with voting rights by controlled undertakings of Wellington Management Group LLP, the aggregate holding of Wellington Management Group LLP crossed upwards a 3% threshold on 25 August 2026.

On 25 August 2026, Wellington Management Group LLP (taking into account the holding of its affiliates) owned 5,846,454 voting rights, representing 3.01% of the total number of shares issued by the company (194,505,658).

2. Content of the notification

- **Reason for the notification:** Acquisition or disposal of voting securities or voting rights.
- **Notification by:** A parent undertaking or a controlling person.
- **Persons subject to the notification requirement:**

Name	Address (for legal entities)
Wellington Management Group LLP	280 Congress Street, Boston, MA 02210, USA


- **Date on which the threshold is crossed:** 25 August 2026.
- **Threshold crossed (in %):** 3%.
- **Denominator:** 194,505,658.



- Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Wellington Management Group LLP	0	0		0,00%	
Wellington Management Hong Kong Ltd	0	238.946		0,12%	
Wellington Management International Ltd	0	593.014		0,30%	
Wellington Management Company LLP	0	4.739.990		2,44%	
Wellington Management Europe GmbH	0	274.504		0,14%	
Subtotal		5.846.454		3,01%	
TOTAL		5.846.454	0	3,01%	0,00%

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0,00%	



UCB News


TOTAL (A & B)		# of voting rights	% of voting rights
CALCULATE		5.846.454	3,01%


- **Chain of controlled undertakings through which the holding is effectively held**

Wellington Management Company LLP is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Management Group LLP. Wellington Management Hong Kong Ltd, Wellington Management International Ltd and Wellington Management Europe GmbH are direct controlled undertakings of Wellington Management Global Holdings, Ltd. which, in turn, is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Management Group LLP. The shares are registered in the names of the Accounts or nominees according to their respective holdings.

- **Additional information**

Wellington Management Company LLP, Wellington Management Hong Kong Ltd, Wellington Management Europe GmbH and Wellington Management International Ltd are investment management companies and can exercise the voting rights at their discretion in the absence of specific instructions from the beneficial owners of the shares.





UCB News

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following [link](#).

For further information, contact UCB:

Investor Relations

Yvonne Naughton
T: +44.175.344.7521
Yvonne.Naughton@ucb.com

Sahar Yazdian
T: +32.2.559.9137
sahar.yazdian@ucb.com

Corporate Communications

Laurent Schots
T+32 2 559 92 64
laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB).

